232 related articles for article (PubMed ID: 38060302)
1. Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in China.
Zhang S; Li J; Xu R; Chen Q; Sun G; Lin Y; Cao Y; Chen Y; Geng C; Teng Y; Nie J; Li X; Xu G; Liu X; Jin F; Fan Z; Luo T; Liu H; Wang FS; Jiang Z
JMIR Public Health Surveill; 2023 Dec; 9():e46009. PubMed ID: 38060302
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
3. The Actual Status of Hospitals as COVID-19 Vaccination Clinics in China and Safety Monitoring of Inactivated Vaccine: A Cross-Sectional Study.
Huang J; Zhang MQ; Huang MZ; Lin GM
Disaster Med Public Health Prep; 2022 Aug; 17():e256. PubMed ID: 36017705
[TBL] [Abstract][Full Text] [Related]
4. Self-Reported adverse events among Chinese healthcare workers immunized with COVID-19 vaccines composed of inactivated SARS-CoV-2.
Cheng Y; Li T; Zheng Y; Xu B; Bi Y; Hu Y; Zhou YH
Hum Vaccin Immunother; 2022 Nov; 18(5):2064134. PubMed ID: 35452357
[TBL] [Abstract][Full Text] [Related]
5. Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study.
Mei Q; Hu G; Yang Y; Liu B; Yin J; Li M; Huang Q; Tang X; Böhner A; Bryant A; Kurts C; Yuan X; Li J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264438
[TBL] [Abstract][Full Text] [Related]
6. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
7. Attitudes towards and safety of the SARS-CoV-2 inactivated vaccines in 188 patients with systemic lupus erythematosus: a post-vaccination cross-sectional survey.
Tang Q; Li F; Tian J; Kang J; He J
Clin Exp Med; 2023 Jun; 23(2):457-463. PubMed ID: 35612692
[TBL] [Abstract][Full Text] [Related]
8. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 vaccination in patients with primary immunodeficiencies: an international survey on patient vaccine hesitancy and self-reported adverse events.
Pergent M; Haerynck F; Hoste L; Gardulf A
Front Immunol; 2023; 14():1166198. PubMed ID: 37143673
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 vaccination status, side effects, and perceptions among breast cancer survivors: a cross-sectional study in China.
Xu Y; Li L; Li X; Li H; Song Y; Liu Y; Chen C; Zhan H; Wang Z; Feng X; Liu M; Wang Y; Liu G; Qu Y; Li Y; Li Y; Sun Q
Front Public Health; 2023; 11():1119163. PubMed ID: 37139378
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study.
Massoud F; Ahmad SF; Hassan AM; Alexander KJ; Al-Hashel J; Arabi M
Seizure; 2021 Nov; 92():2-9. PubMed ID: 34391030
[TBL] [Abstract][Full Text] [Related]
14. Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study.
Xiong X; Wong CKH; Au ICH; Lai FTT; Li X; Wan EYF; Chui CSL; Chan EWY; Cheng FWT; Lau KTK; Lee CH; Woo YC; Lui DTW; Wong ICK
Thyroid; 2022 May; 32(5):505-514. PubMed ID: 35216517
[No Abstract] [Full Text] [Related]
15. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ
Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939
[TBL] [Abstract][Full Text] [Related]
16. Adverse events and overall health and well-being after COVID-19 vaccination: interim results from the VAC4COVID cohort safety study.
Rogers A; Rooke E; Morant S; Guthrie G; Doney A; Duncan A; Mackenzie I; Barr R; Pigazzani F; Zutis K; MacDonald TM
BMJ Open; 2022 Jun; 12(6):e060583. PubMed ID: 35649591
[TBL] [Abstract][Full Text] [Related]
17. Adverse Events Following COVID-19 Vaccination in Adolescents: Insights From Pharmacovigilance Study of VigiBase.
Kim DH; Kim JH; Oh IS; Choe YJ; Choe SA; Shin JY
J Korean Med Sci; 2024 Mar; 39(8):e76. PubMed ID: 38442719
[TBL] [Abstract][Full Text] [Related]
18. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
National Immunization Advisory Committee (NIAC) Technical Working Group (TWG), Influenza Vaccination TWG
Zhonghua Liu Xing Bing Xue Za Zhi; 2022 Oct; 43(10):1515-1544. PubMed ID: 36456484
[TBL] [Abstract][Full Text] [Related]
19. Safety monitoring in inactivated COVID-19 vaccines by clinical pharmacists from a single center in China.
Hu M; Guo W; Liu L; Yang Y; Xu Q; Cheng F; Zeng F; Zhang Y
Front Immunol; 2022; 13():882919. PubMed ID: 36131922
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
Jin P; Guo X; Chen W; Ma S; Pan H; Dai L; Du P; Wang L; Jin L; Chen Y; Shi F; Liu J; Xu X; Zhang Y; Gao GF; Chen C; Feng J; Li J; Zhu F
PLoS Med; 2022 May; 19(5):e1003953. PubMed ID: 35617368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
